Changes in Hong Kong stocks | Hebo Pharmaceutical-B (02142) rose more than 9%, and its stock price increased nearly 3 times during the year and received the down payment under the Windward Bio licensing agreement

The Zhitong Finance App learned that Hebo Pharmaceutical-B (02142) rose more than 9%, and its stock price increased nearly 3 times during the year. As of press release, it rose 9.01% to HK$7.38, with a turnover of HK$4.402,200.

According to the news, Hebo Pharmaceutical recently announced that according to the license agreement it signed with Columbite with Windward Bio AG for HBM9378/SKB378, the company has received corresponding down payments, including cash payments and shares in Windward Bio's parent company. Under the license agreement signed on January 10, Windward Bio has obtained the exclusive license of HBM9378/SKB378 to conduct research, development, production and commercialization worldwide (excluding Greater China and some Southeast Asian and West Asian countries). Heplatinum Pharmaceuticals and Collumbotai are entitled to a total of up to $970 million in down payments and milestone payments, as well as tiered royalties based on single- to double-digit percentages of net sales.

Hebo Pharmaceuticals previously announced that profit for the year ending December 31, 2024 is expected to be between RMB 7.3 million and RMB 22 million. During the period, the company's cash profit reached a record high of RMB 220 million. Furthermore, the company said it has repurchased a total of 8.146 million shares on the open market in 25 years, with a total value of nearly HK$30 million. This development reflects the company's confidence in its business prospects and prospects, and shows that the company's management believes that the current valuation is out of touch with the company's intrinsic value.